Business
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alignment reached on key elements of ATH434 Phase 3 development programMELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3
About this update from Alterity Therapeutics Ltd.
[{"type":"image","alt":"ALTERITY THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"ALTERITY THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":222,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7YAvEB_IaVX9uXkeY1FY4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNg--/https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62","width":222,"height":56}},"lazy":false},{"type":"text","content":"Alignment reached on key elements of ATH434 Phase 3 development program","length":71,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA).","length":493,"tagName":"p"},{"type":"text","content":"The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans related to the clinical pharmacology and non-clinical development elements of the program.","length":293,"tagName":"p"},{"type":"text","content":"“This meeting confirms alignment with the FDA in two key disciplines and represents an important step toward initiation of the Phase 3 program,” said David Stamler, M.D., Chief Executive Officer of Alterity. “In addition, we will also be seeking agreement with the FDA on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design. Today’s favorable outcome sets the stage for our future discussions, culminating in an End-of-Phase 2 meeting that remains on track for mid-year 2026.”","length":498,"tagName":"p"},{"type":"text","content":"About Alterity Therapeutics Limited ","length":35,"tagName":"p"},{"type":"text","content":"Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases....